



U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT

Docket Number:
12961/46102

Application Number
10/766,263

Filing date
January 27, 2004

Examiner
Z.C. TUCKER

Art Unit
1624

Invention Title

**NOVEL DERIVATIVES OF 3,3'-
DIPHENYLPROPYLAMINES**

Inventor(s)
MEESE, et al.

Address to:

Mail Stop Amendment
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

I hereby certify that this correspondence is being deposited with the
United States Postal Service with sufficient postage as first class mail in an
envelope addressed to: Mail Stop Amendment Commissioner for Patents, P.O.
Box 1450, Alexandria, VA 22313-1450 on: February 14, 2006

By: Joseph A. Coppola
Joseph A. Coppola (Reg. No. 38,413)

1. In accordance with the duty of disclosure under 37 C.F.R. § 1.56 and in conformance with the procedures of 37 C.F.R. §§ 1.97 and 1.98 and M.P.E.P. § 609, attorneys for Applicant hereby brings the attached references to the attention of the Examiner. These references are listed on the attached modified PTO Form No. 1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.
2. The filing of this Information Disclosure Statement and the attached PTO Form No. 1449, shall not be construed as an admission that the information cited is prior art, or is considered to be material to patentability as defined in 37 C.F.R. § 1.56(b).
3. A copy of each patent, publication or other information listed on the modified PTO form 1449 are enclosed unless otherwise noted.
4. It is believed that no fees are due in connection with this Information Disclosure Statement. However, should any fees be due, the Commissioner is authorized to charge or credit any over payment to Deposit Account No. 11-0600. A duplicate copy of this communication is enclosed for charging purposes.

Dated: February 14, 2006

By:

Joseph A. Coppola
Joseph A. Coppola (Reg. No. 38,413)

KENYON & KENYON
One Broadway
New York, N.Y. 10004
(212) 425-7200 (Telephone)
(212) 425-5288 (Facsimile)
CUSTOMER NO. 26646



FEB 21 2006

IAP86

OIPE

U.S. PATENT & TRADEMARK OFFICE

2006

APRIL

2006

10/766,263

12961/46102

Z.C. TUCKER

January 27, 2004

1624

U.S. PATENT DOCUMENTS*

EXAMINER INITIAL

PATENT/PUBLICATION NUMBER

PATENT/PUBLICATION DATE

NAME

CLASS

SUBCLASS

FILING DATE*

2003/0152624

August 14, 2003

Aldrich et al.

2003/0158176

August 21, 2003

Richards et al.

2004/064821

April 1, 2004

Rousselle

3,216,841

July 19, 1966

Zenitz

6,310,248

October 30, 2001

Andersson et al.

6,566,537

May 20, 2003

Andersson et al.

6,689,916

February 10, 2004

Andersson et al.

U.S. PATENT DOCUMENTS*

*- copies of U.S. references are not enclosed

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL

DOCUMENT NUMBER

DATE

COUNTRY

CLASS

SUBCLASS

TRANSLATION

766,207

December 22, 1952

DE

YES

831,799

June 7, 1996

EP

872,233

April 14, 1997

EP

948,321

December 10, 1997

EP

957,073

May 12, 1998

EP

1,025,041

February 24, 1964

GB

WO 02/089773

November 14, 2002

PCT

WO 02/11702

February 14, 2002

PCT

WO 03/002059

January 9, 2003

PCT

WO 03/007918

January 30, 2003

PCT

WO 03/020241

March 13, 2003

PCT

WO 03/026564

April 3, 2003

PCT

WO 03/035599

May 1, 2003

PCT

WO 03/039464

May 15, 2003

PCT

WO 03/063834

August 7, 2003

PCT

WO 03/099268

December 4, 2003

PCT

WO 03/103637

December 18, 2003

PCT

WO 03/106421

December 24, 2003

PCT

WO 04/019892

March 11, 2004

PCT

WO 98/43942

October 8, 1998

PCT

WO 98/56359

December 17, 1998

PCT

WO 99/58478

November 18, 1999

PCT

NO

Page 1

OTHER DOCUMENTS

EXAMINER INITIAL		AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
		Lipinski, et al., "Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings" Elsevier Advanced Drug Delivery Reviews Vol. 23, pp. 3-25, 1997
		Netzer, et al., "Screening lead compounds for QT interval prolongation" Drug Discovery Today Vol. 6, No. 2, pp.78-84, January 2001
		Nilvebrant & Sparf, "Differences between Binding Affinities of some Antimuscarinic Drugs in the parotid Gland and those in the Urinary Bladder and Ileum" Acta Pharmacol. et toxicol. Vol. 53, No. 4, pp. 304-313, October 1983
		Pharmacology/Toxicology Review from Application Number 21-518, Center for Drug Evaluation and Research, pp. 1-3.
		Roy, et al., "HERG, a Primary Human Ventricular Target of the Nonsedating Antihistamine Terfenadine" Circulation Vol. 94, No. 4, pp. 817-823, August 15, 1996

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	